文献速递中医内科中药与中成药合理使用

基于代谢组学探索AECOPD中医证候疗效评价生物标志物

Exploration of biomarkers for efficacy evaluation of traditional Chinese medicine syndromes of acute exacerbation of chronic obstructive pulmonary disease based on metabolomics.
PubMed 文献 · Front Pharmacol · 2024-01-26

本研究纳入69例AECOPD痰热壅肺证或痰湿壅肺证患者,在常规治疗基础上分别加用清热化痰或燥湿化痰颗粒治疗7天,治疗前后临床症状体征评分、CAT、mMRC、NEU%和CRP均降低(p<0.05)。血清代谢组学显示痰热壅肺证组13种、痰湿壅肺证组16种差异代谢物(p<0.05,VIP≥1.00),部分代谢物与临床指标相关,提示血清代谢物可能是客观评价中医证候疗效的潜在指标。

要点

  • 痰热壅肺证与痰湿壅肺证AECOPD患者治疗后临床症状体征评分、CAT、mMRC、NEU%和CRP均较治疗前降低(p<0.05)。
  • 痰热壅肺证组筛选出13种差异代谢物,痰湿壅肺证组16种(p<0.05,VIP≥1.00)。
  • 痰热壅肺证组多种LPC与临床症状体征评分、WBC、NEU%及CRP负相关;痰湿壅肺证组L-苯丙氨酸与CRP正相关,2-甲基丁酰肉碱与临床症状体征及CAT评分正相关,DL-肉碱与临床症状体征评分正相关(p<0.05)。

核心结论

  • 血清代谢物可能是客观评价AECOPD中医证候疗效的潜在指标,但需进一步大样本对照试验验证。

研究设计与样本

  • 研究纳入69例AECOPD患者,其中痰热壅肺证41例、痰湿壅肺证28例,在常规治疗基础上分别加用清热化痰或燥湿化痰颗粒治疗7天。
  • 治疗前后采集临床症状体征评分、mMRC、CAT及炎症指标(WBC、NEU%、CRP),并采集血清进行代谢组学分析以筛选差异代谢物。

主要发现

  • 两组治疗后临床症状体征评分、CAT、mMRC、NEU%和CRP水平均低于治疗前(p<0.05)。
  • 痰热壅肺证组治疗前后有13种差异代谢物,痰湿壅肺证组有16种(p<0.05,VIP≥1.00)。
  • 痰热壅肺证组LPC(16:0)、LPC(17:1)、LPC(18:3)、LPC(18:2)、LPC(17:0)与临床症状体征评分负相关(p<0.05);LPC(16:0)、LPC(17:1)、LPC(16:1)、LPC(17:0)与WBC和NEU%负相关(p<0.05);LPC(16:0)与CRP负相关。
  • 痰湿壅肺证组L-苯丙氨酸与CRP正相关(p<0.05);2-甲基丁酰肉碱与临床症状体征评分及CAT评分正相关(p<0.05);DL-肉碱与临床症状体征评分正相关(p<0.05)。

临床怎么用

  • 对于AECOPD痰热壅肺证或痰湿壅肺证患者,可在常规治疗基础上分别联合清热化痰或燥湿化痰颗粒治疗7天,并观察临床症状体征评分、CAT、mMRC及炎症指标变化。
  • 血清LPC、L-苯丙氨酸、2-甲基丁酰肉碱、DL-肉碱等代谢物与临床指标相关,可作为中医证候疗效评价的潜在生物标志物参考,但尚需大样本对照试验验证。

局限性

  • 研究结论提示需进一步大样本对照试验验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Traditional Chinese medicine (TCM) is effective for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD); however, there is no objective index for the evaluation of TCM syndrome efficacy. This study aimed to screen biomarkers related to the efficacy of TCM syndrome using metabolomics. Methods: We recruited AECOPD patients with phlegm-heat congesting lung (PH)/phlegm-damp amassing lung (PD) syndrome and treated them with Chinese herbal medicine (Qingre Huatan or Zaoshi Huatan granules) in addition to conventional medicine for 7 days. Data on clinical symptoms and sign scores, modified British Medical Research Council (mMRC), COPD assessment test (CAT), and inflammation indicators, including white blood cell (WBC) count, percentage of neutrophil count (NEU%), and C-reactive protein (CRP), were collected before and after treatment to evaluate the therapeutic effect. Serum samples were collected before and after treatment for metabolomic analysis to screen differential metabolites. Results: A total of 69 patients with AECOPD were enrolled, including 41 and 28 patients in the PH and PD groups, respectively. The clinical symptoms and sign scores, CAT, mMRC, NEU%, and CRP levels after treatment were lower than those before treatment in both groups (p < 0.05). Serum metabolomics analysis showed that there were 13 differential metabolites in the PH group and 16 differential metabolites in the PD group before and after treatment (p < 0.05, variable importance projection (VIP) ≥ 1.00). In the PH group, lysophosphatidylcholine (LPC) (16:0), LPC (17:1), LPC (18:3), LPC (18:2), and LPC (17:0) negatively correlated with clinical symptoms and sign scores (p < 0.05); LPC (16:0), LPC (17:1), LPC (16:1), and LPC (17:0) negatively correlated with WBC (p < 0.05) and NEU% (p < 0.05); and LPC (16:0) negatively correlated with CRP levels. In the PD group, L-phenylalanine positively correlated with CRP levels (p < 0.05), and 2-methylbutyroylcarnitine positively correlated with clinical symptoms and sign (p < 0.05) and CAT scores (p < 0.05). DL-carnitine positively correlated with clinical symptoms and sign scores (p < 0.05). Conclusion: Serum metabolites may be potential indicators to objectively evaluate the efficacy of TCM syndromes; however, further large controlled trials are required to verify these findings.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hailong Z, Yimei S, Yan D, et al. Exploration of biomarkers for efficacy evaluation of traditional Chinese medicine syndromes of acute exacerbation of chronic obstructive pulmonary disease based on metabolomics. Front Pharmacol. 2024. PMID: 38344179. doi:10.3389/fphar.2024.1302950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。